

CUTTING-EDGE INNOVATIONS IN LIFE SCIENCES & MEDICAL TECHNOLOGIES

Providing creative legal solutions for disruptive technologies.

Innovation is the driver of the life sciences industry, and that is especially true in today's market with the explosion of several cutting-edge technologies offering patients and consumers novel and groundbreaking medical advancements. Developments in artificial intelligence, gene editing, additive manufacturing, robotics and telemedicine/digital health have revolutionized discovery, development and manufacturing of biologics, drugs, diagnostics and medical devices. The breakneck pace of technology, however, results in companies facing unique legal challenges to address traditional and unprecedented IP, regulatory and data and privacy issues. Our global team has extensive experience and a deep understanding of these spaces, and the bandwidth to keep pace with the evolving legal and regulatory landscape, offering our clients strategic and creative legal solutions to both protect and advance their innovative technologies. Our attorneys are able to provide representation specific to the needs of companies developing emerging technologies, as highlighted by the following examples:


- IP and Trade Secret Protection: Our IP attorneys have medical and technological backgrounds, which allow them to understand the unique challenges associated with protecting software and artificial intelligence. They also understand the importance of mitigating against the threats of cybersecurity attacks and of reverse engineering through additive manufacturing.
- Regulatory: Our regulatory attorneys closely follow governmentissued draft guidance documents, participate in government requests for feedback on developing regulations, and actively engage with the FDA in order to help clients navigate developing clearance and compliance issues.
- Corporate: Our transactional attorneys are well versed in negotiating contracts and structuring deals from financing, to licensing and strategic partnerships, and through mergers and acquisitions involving disruptive technologies.
- Products Liability: Our team also understands that, when innovation outpaces the law, there is an increased risk of products liability exposure. We have experience consulting and advising clients on best pre- and post- market practices to help mitigate these risks. If necessary, we also have a deep bench of experienced Trial attorneys to defend clients against individual claims or complex mass tort litigation.

RANKINGS

 Ranked by Legal 500: United States 2023 as a LEADING LAW FIRM in Life Sciences



Ranked by LMG Life Sciences
2024 among leaders in
Patent Prosecution



RANGE OF SERVICES

- ► IP Licensing/Diligence
- IP Strategy/Prosecution
- ► IP Litigation
- Regulatory
- Corporate Formation
- Financings
- Exits
- Stakeholder Disputes
- Collaborations/Partnering
- Commercial Contracts
- Corporate Governance
- Commercial Litigation
- Products Liability and Toxic Torts
- White Collar/Government Regulatory
- Employment and Labor
- Benefits
- Immigration Services and Compliance
- Non-Compete & Trade Secrets

REPRESENTATIVE MATTERS

- Represented EVAXION BIOTECH (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of Al-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, in its \$30 million initial public offering.
- Represented ALLEVI, INC., a manufacturer of 3D bioprinters and bioinks trusted by leading researchers worldwide, in the \$9.5 million sale of its business to 3D Systems (NYSE: DDD), a provider of 3D printing and digital manufacturing solutions.
- Represent a data storage company for patent applications in biochip areas, such as DNA and protein chips and microarray synthesis, or lab-on-a-chip synthesis.
- Drafted licensing and privacy agreements for a digital health company using an AI-driven application to diagnose, treat and support patients with traumatic brain injuries.
- Counsel to a medtech company offering customized 3D-printed radiology shields for use in cancer patients, assisting the company with drafting corporate formation documents, strategizing fundraising initiatives and negotiating manufacturing and consulting agreements.
- Represented TISSUE ANALYTICS, a digital health company that develops AI-powered software solutions that serve clinicians, industry, payer and clinical research players in the wound care space, in a range of areas from formation to its sale to Net Health, a provider of cloud-based electronic health record software for specialized care settings and a portfolio company of the Carlyle Group, Level Equity and Silversmith Capital Partners.
- Represented COWEN AND COMPANY, LLC, acting as sales agent in a \$30 million at the market equity offering of common stock for Corindus Vascular Robotics, Inc. (Nasdaq: CVRS), which designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures.
- Advised a Canadian research and economic agency concerning a collaboration with a U.S. medical device manufacturer in the field of orthopedic robotics.
- Counseled a U.S. gene editing company with foreign ownership through the strategic acquisition of a competitor and the regulatory process of the Committee on Foreign Investment in the United States.





OFFICE LOCATIONS & REACH



UNITED STATES

Atlanta	Miami
Austin	New Jersey North
Baltimore	New Jersey South
Boca Raton	New York
Boston	Philadelphia
Chicago	Pittsburgh
Dallas	San Diego
Fort Worth	San Francisco
Houston	Silicon Valley
Las Vegas	Washington, D.C.
Los Angeles	Wilmington

INTERNATIONAL

Hanoi	Shanghai
Ho Chi Minh City	Singapore
London	Sydney
Myanmar	

- > Also satellite offices, including Bangor and Portland, Maine;
- Bangor and Portland, Maine; Berwyn, Pennsylvania; and Seattle, Washington
- > Alliances in Mexico and throughout Latin America
- > Leadership position with international network of independent law firms

FOR MORE INFORMATION, PLEASE CONTACT:

SEAN K. BURKE, Partner 202.776.5236 | SBurke@duanemorris.com

JASON LUO, PH.D., Partner 215.979.1809 JLuo@duanemorris.com

SHANNON HAMPTON SUTHERLAND, Partner

215. 979.1104 SHSutherland@duanemorris.com

ELIZABETH G. HODGSON, Special Counsel 215.979.1262 | EHodgson@duanemorris.com

This publication is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The invitation to contact the attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.